S/N 10/502,119 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

LAUTT ET AL.

Examiner:

PURNELL

Serial No.:

10/502,119

Group Art Unit:

1632

Filed:

JANUARY 12, 2005

Docket No.:

14430.6USWO

Title:

USE PHOSPHODIESTERASE ANTAGONISTS TO TREAT INSULIN

RESISTANCE

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. §1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.

P.O. Box 2903

Minneapolis, Minnesota 55402-0903

612.332.5300

Date: July 13, 2007

Brian R. Dorn Reg. No. 57,395

BDorn:jm

23552
PATENT TRADEMARK OFFICE

Date Mailed: July 13, 2007 Sheet 1 of 1

FORM 1449*	INFORMATION DISCLOSURE STATEMENT	Docket Number: 14430.6USWO	Application Number: 10/502,119		
IN AN APPLICATION		Applicant: Lautt			
	(Use several sheets if necessary)	Filing Date: January 12, 2005	Group Art Unit: 1632		

	T		Ţ	J.S. PATENT DOCUMEN	 				
EXAMINER INITIAL	DOCUMENT NO.		DATE	NAME	CLASS			NG DATE ROPRIATE	
	2003/0114469 2003/0166662 2003/0181461		6-19-2003	Cohen					
			9-4-2003	Fryburg et al.					
			9-25-2003	Lautt					
			FOR	REIGN PATENT DOCUM	1ENTS				
	DOCUMENT NO.		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	
				1					
				And the second s					
		ОТИГР	DOCUMENT	S (Including Author, Title,	Dota Partinant I	Pages Eta)		L	
			Requirement of	dated September 9, 2005 in	· · · · · · · · · · · · · · · · · · ·		at. Appl. Pub	. No.	
		Correia et al., "Hepatic guanyl cyclase inhibition induced HISS-dependent insulin resistance," Proc. West. Pharmacol. Soc. 45: 57-58 (2002).							
		Sadri et al., "Blockade of hepatic nitric oxide synthase causes insulin resistance," Am. J. Physiol. 277: G101-G108 (1998).							
		Xie et al., "Insulin sensitivity tested with a modified euglycemic technique in cats and rats," J. Pharmaco Toxicol. Methods 35: 77-82 (1996).						acol.	
							-		

23552
PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.